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Hypertensive 
heart disease in Africa
Blood pressure control
There are few studies in Africa on blood pressure control. 
However, all the studies tended to show that blood pressure 
control in Africa is less than optimal. For example, in a study by 
Isezuo, et al.(10) 42.7% blood pressure control rate was achieved 
among hypertensives managed in a specialised health setting in 
Nigeria. Data from the United States(11) however revealed that 
advanced countries have not fared better as only 27% of 
hypertensives had good blood pressure control which was still 
far below the goal of 50%. In another study in Cape Town, 
South Africa, Rayner, et al.(12) found that only 39.8% of hyper-
tensives achieved good blood pressure control rate, a fi gure which 
again was still less than optimal.
LEFT VENTRICULAR HYPERTROPHY                         
Left ventricular hypertrophy (LVH) is the best studied marker 
of hypertensive heart disease.(13) Left ventricular hypertrophy is 
a recognised complication of systemic hypertension. Although 
for many years LVH was thought to be a benefi cial compen-
satory mechanism for maintaining normal wall stress in left 
ventricular (LV) pressure and volume overload,(14) epidemio-
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INTRODUCTION                                                             
Hypertension is an important public health problem worldwide. 
It is also the commonest cardiovascular disease among black 
Africans.(1) Hypertension is an acknowledged potential risk factor 
in the development of cardiovascular diseases like stroke, 
coronary heart disease, renal failure and congestive heart failure.(2,3) 
The heart is a common target in hypertension.
The response of the heart to the stress/afterload imposed on 
the left ventricle by the progressively increasing arterial blood 
pressure is described as hypertensive heart disease.(4) Hyper-
tension is still a very big burden (economically) on the African 
continent(5-7) despite advances in clinical assessment, investigation, 
diagnosis, management and prevention.
Epidemiology 
There are different prevalent rates of hypertension in African 
communities. In general however, the prevalence rate in urban 
areas is more than in rural areas. Seedat, et al.(8) for example found 
a prevalence rate of 25% and 9.4% among urban and rural Zulus 
of South Africa respectively. In Nigeria prevalence rates of 9.8% 
and 14.6% were obtained in rural and urban areas.(9) 
Hypertension has become an important public health 
problem in Africa. Currently an epidemiologic transition 
from infectious diseases is going on in the continent and 
the prevalence of chronic diseases like hypertension is 
increasing.  The response of the heart to the stress/after-
load imposed on the left ventricle by the progressively 
increasing arterial blood pressure is described as hyper-
tensive heart disease. Hypertensive heart disease and failure 
are the commonest cardiovascular diseases of Africans. 
Since hypertension is a treatable cardiovascular risk factor, 
there is need to create more awareness about the disease 
and educate our patients concerning drug compliance. 
There is also a need for longitudinal multicentre study in 
Africa, in order to assess the severity and burden of the 




















logical studies using electrocardiography (ECG), and more 
recently echocardiography (Echo), have elucidated the profound 
independent risk of LVH for congestive heart failure, coronary 
events, life threatening dysrrhythmias and cardiac mortality.(15,16) 
Several left ventricular geometric hypertrophy patterns have 
been found in hypertensives using echocardiographic methods(17-19) 
and these are classifi ed into four on the basis of left ventricular 
mass index (LVMI) and relative wall thickness (the ratio of wall 
thickness to cavity diameter) namely concentric, concentric 
remodeling, eccentric and normal geometry. These different 
patterns profoundly infl uence prognosis.(19)  Increasing attention is 
therefore being paid to left ventricular geometry as it becomes 
apparent that these specifi c types may have different patho-
physiologic, aetiologic, diagnostic, therapeutic and prognostic 
signifi cances.(19)
Mayet, et al.(18) in the United Kingdom for example found that 
concentric hypertrophy was present in 40% of hypertensives, 
concentric remodelling in 32%, eccentric hypertrophy in 6% 
and normal geometry in 16%. In Africa, a study of 100 newly 
diagnosed hypertensives by Aje, et al.(20) showed that 72% of 
the patients had abnormal geometric patterns (concentric 
hypertrophy-28%, concentric remodelling-26%, eccentric hyper-
trophy-18%). Ogah, et al.(21) in another study in Ibadan, Nigeria 
found that eccentric hypertrophy was the commonest geometric 
pattern in hypertensives with ECG LVH with strain.
An assessment of a large number of healthy normotensive 
subjects yielded an LVM per body surface of 100g/m2 and 131g/m2 
as the cut off for LVH in women and men respectively. LVH 
was present in 3-7% of those under 50 years of age and 12-40% 
of those between 50 and 80 years of age in the Framingham 
population using these cut off points.(22) Black patients with mild 
hypertension have also been found to have twice the prevalence 
of left ventricular hypertrophy compared with whites who had 
similar arterial pressures.(23)
Physiological hypertrophy
At this juncture it is important for workers in Africa to distinguish 
between physiological and pathological hypertrophy. Several 
workers(24) in Africa have identifi ed the presence of high voltages 
on the ECG among young Africans and some have even 
suggested a revision of the criteria for diagnosis of LVH. 
Others workers in the fi eld have suggested that these are cases of 
physiological hypertrophy in an active segment of the population. 
Cardiac hypertrophy occurs during changes in load and is not 
deleterious in the following conditions: maturation in infancy and 
childhood, pregnancy and exercise.
The difference in these states is the intermittence or transient 
duration of excess load compared with the sustained load of 
hypertension or aortic stenosis. During pregnancy, increased 
stroke volume and cardiac output is accompanied by a substantial 
increase in LV dimension and mass, which regresses over months 
in the postpartum period.(25) 
The concentric hypertrophy that occurs in a trained athlete who 
specialises in sports requiring isometric skeletal muscle contraction 
(i.e. weightlifting, wrestling) or the eccentric hypertrophy that 
occurs in sports requiring isotonic exercise (i.e. long distance 
running, cycling) are consistent with normal LV systolic and 
diastolic function.(26) In the Framingham study, leisure time physical 
activity was associated with increased LV mass in men but not 
in women.(27) In an echocardiographic study by Dzudie, et al.(28) 
on Cameroonian asymptomatic handball players, left ventricular 
mass indexed, relative wall thickness, left ventricular end diastolic 
diameter and left atrial diameter were signifi cantly greater in 
athletes compared to controls. 
PATHOLOGIC HYPERTROPHY: CORRELATES OF    
LEFT VENTRICULAR MASS
Blood pressure
LV mass is more closely related to 24 hour blood pressure than 
casual blood pressure.(29) It is also correlated with offi ce blood 
pressure possibly as a result of job strain.(30) Palmieri, et al.(31) found 
that subjects with inappropriately high LV mass had higher 
ambulatory blood pressures, LV relative wall thickness, and lower 
LV systolic performance than those with normal LV mass.
Race
Signifi cant racial differences exist with respect to LV mass. 
Healthy young blacks have greater LV wall thickness relative to 
whites.(32) The rate of echocardiographically detected left ventri-
cular hypertrophy in blacks with mild hypertension is twice 
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that seen in whites.(23) Gardin, et al.(33) also found that LV mass 
was higher in blacks.
Sex
For any given level males appear to have a 15-20% greater LV 
mass index than women.(34) This may be due to the 15% lower lean 
body mass and maximal oxygen consumption noted in women 
compared with men.(35)
Salt intake
Salt intake is a major risk factor for hypertension. Studies(36-39) 
supporting the role of sodium in the genesis of hypertension 
have shown that there is a positive correlation between urinary 
sodium excretion and the arterial blood pressure. Salt intake is 
 also a strong determinant of LV wall thickness and LV mass. 
Insulin and Insulin Growth Factor-1 (IGF-1)
Insulin and glucose metabolism may affect LV geometry.(40) An 
adverse association has been noted between insulin sensitivity, 
measured by glucose clamp technique and LV wall thickness 
in subjects with essential hypertension.(41) Insulin exerts a 
direct growth promoting effect on cardiomyocytes. IGF-1 may 
also induce cardiac hypertrophy and insulin could stimulate 
muscle growth by binding to the IGF-1 receptors because of 
the structural similarity between the two molecules.(42) IGF-1 is 
increased and associated with LV mass in subjects with essential 
hypertension. Insulin and IGF-1 are independent determinants 
of LV mass and geometry.(43)
Others
Obesity,(44) high alcohol intake,(45) plasma viscosity,(46) physical 
activity,(27) increasing age(47) and genetics(48) have all been shown
 to infl uence LV mass.
DEVELOPMENT OF LEFT VENTRICULAR MASS        
Familial predisposition may contribute to increased LV wall 
thickness as studies have shown the infl uence of genetics on 
LV mass, independent of other factors.(49) Increased LV mass 
precede increases in blood pressure. In the Framingham population 
increased LV mass was associated with development of hyper-
tension.(50) In another study, higher values of LV mass in normo-
tensive children predicted increase in blood pressure over the 
following 4 years.(51)
Various reasons have been adduced for increased LV mass 
preceding onset of elevated blood pressure.  These include, a hyper-
dynamic state with increased cardiac output leading to increased 
LV mass before peripheral arterial resistance and persistent 
hypertension develops; genetic infl uences; unobserved but signi-
fi cant periodic blood pressure rises in normotensive subjects and 
increased psychological stress with associated elevated cate-
cholamine levels which cause increased LV mass before the onset 
of hypertension.
AETIOPATHOGENESIS                                                    
Increased LV mass (LVH) is mainly due to pressure or volume 
overload on the heart.  Common causes of volume overload state 
include mitral and aortic regurgitation, chronic anaemia and 
ventricular septal defects while causes of pressure overload 
states include systemic hypertension, aortic stenosis, coarctation 
of aorta and hypertrophic cardiomyopathy.
It is believed that a mechanical signal initiates a cascade of 
biological events leading to coordinated cardiac growth. The signals 
for volume pressure overload are either quite different or result 
in remarkably different patterns and mechanisms of growth.  There 
is an increased myosin heavy chain synthesis by 35% within hours 
of pressure overload. This increase is initially predicted by an 
increase in translational effi ciency.(52) In volume overload, the 
decrease in the myosin heavy chain degradation rate contributes 
much to the increase in LVM.(53)
Both forms of hypertrophy are accompanied by complex 
changes in gene reprogramming.(54) These changes which include 
re-expression of immature fetal cardiac genes including the 
following:
genes that modify motor unit composition and regulation 
genes that encode hormonal pathways e.g. atrial natriuretic 
factors 
genes that modify energy metabolism
Long term changes in gene expression are still unclear. In hyper-
trophy there is an increase in the number of force generating 
units (sarcomeres) in the myocytes. Mechanical input is transduced 
























nucleus, a possible inducer for this change is local adhesion 
complex in which integrins connect at the internal cytoskeleton of 
the cell to the extracellular matrix.(55)
Tyrosine–phosphorylated kinases and Serine-threonine kinases 
(which make up protein kinase C) are implicated in the signalling 
of hypertrophy.(56) They are found in the extracellular matrix. 
Though the critical steps in transduction are not understood 
but there is evidence that disruption of the cell-cell and cell 
extracellular matrix contact is suffi cient to modulate both cell 
growth and apoptosis,(57) changes in integrin expression and 
possible shedding into adjacent extracellular matrix accompany 
chronic hypertrophy.(58) It raises the potential for disordered 
biochemical signal transduction for growth and suboptimal myocyte 
extracellular matrix coupling for force generation.
Angiotensin II
Some have postulated that angiotensin II, via the ATI receptor 
plays a key role in the induction of hypertrophy because it can 
directly induce the molecular events of early cardiac growth.(59) 
The synthetic machinery is unregulated in hypertrophied rat, 
human myocardium(60) and it is required for the growth of 
stretched neonatal myocytes in vitro.  It is also noteworthy  that 
the observations that pressure overload produces robust hyper-
trophy in transgenic mice with AT1a receptor knockout(61) show 
that angiotensin II is mandatory for load induced hypertrophy. 
Harrap, et al.(62) evaluated correlates of left ventricular mass 
(LVM) in 84 young healthy subjects aged 16-24 and found a 
direct role for angiotensin II in the development of LVH. 
Cardiac renin – angiotensin system has been proposed as an 
important determinant of hypertrophic response.(63) Regression 
analysis showed that plasma angiotensin II, renin and angiotensin 
converting enzyme (ACE) levels correlated signifi cantly with 
LVM. The importance of angiotensin II in the development of 
LVH in hypertensive patients is also suggested indirectly by the 
observation that an ACE inhibitor predictably causes regression of 
LVH more so than other antihypertensive drugs.(64)
Endothelin
Experimental animal studies suggest that endothelin plays a role 
in the development of myocardial hypertrophy in response to 
elevated pressure.(65)
Calcineurin
A calcium calmodulin – dependent phosphatase serves as a master 
switch for clinical hypertrophy. Transgenic mice that overexpress 
components of the calcineurin signalling pathway develop a 
hypertrophic phenotype that can be suppressed by pharma-
cological inhibitors of calcineurin.(66) Calcineurin inhibitors fail to 
suppress experimental hypertrophy in several animal models and 
in humans with  hypertension after cardiac transplantation.(67) 
All these suggest that induced hypertrophy is modulated by 
redundant signalling pathways with the potential for recruitment 
of alternate signalling cascades when a single pathway is 
suppressed.(68)
Metalloproteinases (MMPs)
Matrix metalloproteinases, a family of zinc dependent interstitial 
enzymes and their tissue inhibitors (TIMPS) control the break-
down of collagen.(69) MMPs are of more relevance in volume 
overload hypertrophy in which an increase in MMP activation 
and down regulation of localised tissue inhibitors for the changes 
in the collagen matrix that prompt chamber expansion.(70) The 
role of MMPs in concentric hypertrophy is less understood but 
preliminary observations show that they are activated in 
experimental pressure overload hypertrophy. Studies(71,72) have 
also shown that imbalance between MMPs and TIMPs could lead 
to LVH and diastolic dysfunction. There are still a lot of contro-
versies concerning ventricular remodelling.(73)
Heterometrimeric G Proteins
Many of the hormones and neurotransmitters implicated in the 
initiation and exacerbation of myocardial hypertrophy including 
angiotensin II and endothelin bind to cell membrane receptors 
which couple to a subset of intracellular heterometrimeric G 
proteins, the G (q) subclass. Direct evidence for the importance 
of this subclass is provided by the phenotype of the transgenic 
mice which selectively over express the carboxyl- terminal peptide 
of the alpha subunit G (q).(74)
Genetic tendency
The fi ndings that increased LV mass may precede hypertension 
and that patients with similar degrees of hypertension may have 
marked differences in left ventricular mass suggest that genetic 
factors can promote and retard the development of LVH. This 
is supported by the increased risk for LVH observed in middle 
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aged men with the DD genotype of the ACE gene.(75) The 
increased risk associated with the DD genotype has been 
extended to patients who have recently undergone renal trans-
plantation.(76)
Most of these studies were conducted outside Africa. Since 
there may be differences in the pathogenesis of left ventricular 
hypertrophy in Africa, there is need for similar studies to be 
conducted in Africa.
PROGRESSION OF LEFT VENTRICULAR                      
HYPERTROPHY IN AFRICANS
In view of poor or lack of control of hypertension prevalent 
in Africa, several studies have shown that untreated hypertension 
was capable of slowly and progressively damaging the heart 
muscle until it became large and fl abby.(77-80) Moreover, other 
deleterious factors such as excessive alcohol intake also contri-
buted to the destruction process. These will be discussed further 
later on. 
These studies showed that, following the initial thickening of 
the heart muscle in hypertension, destruction of the heart 
muscle begins and continues unabated if hypertension remains 
untreated, albeit slowly and quietly until it reaches a stage when 
the muscle, together with the important structures embedded 
within it (i.e. the electrical conducting tissues and coronary 
arteries), are completely damaged. Eventually, the heart muscle 
is so destroyed that it is no longer able to support a high 
blood pressure which therefore falls to normal or subnormal levels. 
The patient may at this stage present to the doctor as myo-
cardial disease of unknown cause. Some patients are however 
seen when the blood pressure has not completely normalised 
and this was in the past wrongly attributed to the effect of heart 
failure rather than its cause (reactive hypertension).  
Why does this happen? Further studies(81) of the effect of 
hypertension on the heart have shown the following sequence of 
events. A thickened left ventricle obviously requires supply of 
additional blood compared with a normal ventricle and the heart 
does this by appropriating more blood supply for itself. This 
ensures adequate perfusion and performance of the heart muscle. 
There is no problem with this process if the thickening is mild 
and/or the coronary vessels are healthy enough to ensure 
adequate supply of blood to the thickened myocardial wall. But 
if the thickening continues unabated, either as a result of poor 
high blood pressure control or lack of it, and if the coronary vessels 
are diseased and are not in such a state to ensure adequate 
perfusion of the muscle wall, the entire muscle wall becomes 
relatively ischaemic.  The effect of this is to provoke formation of 
scar tissue within the myocardium. This is known as reactive 
fi brosis.(81,82) The fi rst area of the heart to become relatively 
ischaemic is the area below the lining of the left ventricle due to 
the mode of supply of blood to the heart. This is responsible for 
the common fi nding of T wave inversion in leads V5-V6 of the 
ECG, a phenomenon known as left ventricular strain.(21,83)
Some of the individual muscle fi bers of the left ventricle may 
be damaged or completely destroyed in the process not only by 
the raised blood pressure but also by other injurious factors such 
as excessive alcohol consumption or myocarditis, and are 
similarly replaced by scar tissue.(84-87) This type of scar tissue is 
known as reparative fi brosis.
The end-result of reactive and reparative fi brosis is the same. 
Scar tissue is not designed to contract and squeeze blood like the 
original heart muscle fi bers. Therefore, replacement of heart 
muscle fi bers with this non-contractile scar tissue leads to initial 
stiffness of the heart muscle (diastolic dysfunction) and in Africa, 
it is presumed that the process also leads to weakening of the 
contractile ability of the entire heart (systolic dysfunction) and 
consequently, dilatation and failure. 
It should be noted that it is not only the myocardial fi bers that 
are damaged by formation of scar tissue. The electrical structure 
within the heart muscle is also frequently damaged by this process 
and this causes different grades of heart blocks very often starting 
with left anterior fascicular block, progressing to right bundle 
branch block and ultimately complete heart block. Complete left 
bundle branch block may be seen in those with diffuse left myo-
cardial disease. The destructive process also causes disordered 
passage of electrical currents across the myocardium creating 
re-entry mechanisms within it during activation. These result in 
various forms of arrhythmias.
Left atrial enlargement occurs early in hypertension and is due to 





















diastolic dysfunction. A study in our centre(88) showed a 15% 
prevalence rate of left atrial enlargement in hypertension. 45% 
of hypertensives with echo-derived LVH also had enlarged left 
atrium. Age, female gender, obesity and LVH were the factors 
identifi ed to predict left atrial size in our patients.
Generally, an increase in left atrial size correlates closely with 
chronicity of hypertension and severity of diastolic dysfunction. 
The results of Framingham studies also showed that left atrial size 
is an important predictor of atrial fi brillation. However, while 
atrial fi brillation is often caused by enlarged atrium, left atrial 
abnormalities (structural and functional) are also well-recognised 
causes.
Because of these events, those who work in the fi eld of hyper-
tension in Africa must realise that one of the major goals of 
treatment of patients with hypertension is regression of left 
ventricular hypertrophy and appropriate drugs such as the 
angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers (ACEI/ARBs) are now available for this purpose.(89)
HAEMODYNAMICS OF HYPERTENSION IN AFRICA
These are similar to what obtains in the rest of the world. The 
left ventricle retains a normal cavity size in mild hypertension.(90) 
As the level of hypertension becomes moderately or severely 
increased, signifi cant cavity dilatation develops.(77) Cardiac index 
is increased in mild hypertensives, normal in moderate ones 
but decreased in severe cases. Systemic vascular resistance is as 
expected raised, the rise increasing exponentially with the severity 
of hypertension. The degree of myocardial hypertrophy also tends 
to increase progressively with elevated blood pressure becoming 
more marked in those with moderate and severe hypertension. 
Left ventricular stroke work and power and pressure time/beat 
increased with severity of hypertension indicating increased 
myocardial oxygen consumption. This increase in myocardial 
oxygen consumption occurs without a corresponding increase in 
myocardial function. Myocardial contractility indices too decrease in 
those with moderate and severe hypertension.(90)
When heart failure sets in, heart rate increases as expected, 
ejection fraction drops while all the other myocardial contractility 
indices deteriorate.(77,90) Despite a drop in stroke volume and 
cardiac index, systemic vascular resistance remains elevated 
creating a situation whereby a weak heart is contracting against a 
high vascular resistance. This has the effect of causing a rapid 
deterioration of the patient leading to a descent into more severe 
heart failure and even cardiogenic shock. Recovery of the patient 
is dependent on normalisation of the systemic vascular resistance.
CLINICAL PRESENTATION                                            
The incidence of hypertensive heart disease and heart failure is 
high among hypertensives in Africa.(91) Like in other parts of the 
world, majority of patients with hypertension are asymptomatic 
when they fi rst present in the clinic. In our centre, many of the 
patients who present with diastolic dysfunction may be sympto-
matic or asymptomatic and clinically, diastolic dysfunction is 
associated with presence of S4 on cardiac auscultation. Studies 
from Nigeria have shown that diastolic dysfunction is present in 
70% of Nigerian hypertensives, and about 10% of these have 
heart failure with normal systolic function. The majority of the 
patients with hypertensive heart failure in Africa however have 
varying degrees of systolic dysfunction and based on the 
experienced gained at our institution we propose the recognition 
of four distinct stages of the disease (Falase, unpublished 
observations).
Stage 1 - This is the stage of asymptomatic systolic dysfunction. 
It can only be detected by echocardiography. Cardiac output is 
maintained by an increase in heart rate but systemic vascular 
resistance is high. Improvement is dependent on control of BP, 
preferably with the initial use of ACEI/ARBs and thiazide diuretics.
Stage 2 - is characterised by a further decrease in the degree of 
LV systolic function progressing into the stage of symptomatic 
systolic dysfunction. Cardiac output may drop or still be main-
tained by tachycardia but there is a further rise in Systemic Vascular 
Resistance (SVR). High SVR increases the work of the already 
compromised heart and this creates a vicious cycle for the heart 
of the patient. Consequently, LV failure progressively increases 
and S3 or S4, or S3 and S4 become audible on cardiac auscul-
tation. BP is still recognisably high, usually about 160/100mmHg 
and above.
Stage 3 - occurs with unrelenting hypertension and at this stage 
full blown congestive cardiac failure develops. Cardiac output 
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drops further still, because although there is tachycardia, this 
cannot compensate for the drop in stroke volume. SVR on the 
other hand remains high and there is therefore a rapid decline in 
cardiac function. On auscultation S3 with or without mitral 
regurgitation are audible. In later stages, functional tricuspid 
regurgitation due to RV/RA dilatation develops. Measured BP is 
above 160/90mmHg but later on systolic BP drops while diastolic 
BP hovers between 90-95mmHg. This causes an abnormally low 
pulse pressure. The patient at this stage requires treatment with 
ACEI/ARBs together with diuretics starting with intravenous 
frusemide to remove gut oedema and permit adequate drug 
absorption. This is followed by the use of thiazide diuretics which 
are effective in controlling the blood pressure of the patients and 
at the same time removing excess fl uid. It should be noted that 
the blood pressure may sometimes, depending on the myo-
cardial reserve, rise to greater levels following recovery from heart 
failure. At this stage the patient may require other anti-
hypertensive drugs for control of high blood pressure.
Stage 4 - At this stage BP drops to hypotensive levels. Cardiac 
output drops further too while SVR remains the same or may 
rise further. Such patients are in cardiogenic shock which 
requires powerful inotropic drugs like dopamine or dobutamine 
infusion for treatment. ACEI/ARBs are contraindicated at this 
stage because of the low BP.  Frusemide is the preferred diuretic.
DIAGNOSIS                                                                      
Physical examination is useful in the diagnosis of left ventricular 
hypertrophy. By palpating the apex beat, it gives a clue to the 
presence of cardiomegaly or left ventricular hypertrophy with or 
without dilatation (i.e. displaced or heaving apex beat). 
In the past, indirect methods were available for the estimation of 
the left ventricular size and these included chest x-ray (CXR), 
vectorcardiography and electrocardiography (ECG). Although 
these indirect methods give useful information and high specifi city, 
they have lower sensitivity and predictive accuracy compared 
with newer technologies.
A chest x-ray is still useful in Africa as it provides a cheap 
method of diagnosing cardiomegaly and left ventricular enlarge-
ment. A cardiothoracic ratio (CTR) greater than 50% is accepted 
as an indication of cardiomegaly while left ventricular enlarge-
ment is diagnosed when the apex of the heart is displaced to 
the left and downwards, sometimes below the diaphragm. Very 
often there is also unfolding of the aorta.
Electrocardiography is similarly cheap and more widely available 
than echocardiography. Echocardiography is a more expensive 
procedure although a more accurate form of investigation. 
Magnetic resonance imaging, thallium imaging and ultra fast CT 
scanner are other advanced forms of investigations although 
they are very expensive and are not widely available in Africa.  
  
Some of the eletrocardiographic changes in LVH include increase 
in QRS voltage, increase in QRS duration and repolarisation 
abnormalities. Compared with echocardiographic criteria for 
LVH however, ECG sensitivity is extremely low and it also 
exhibits limited accuracy.(92)
Interethnic differences in ECG characteristics which have been 
demonstrated especially in blacks are due to the higher prae-
cordial QRS voltages observed in blacks.(93,94)
Several studies(95,96) including those conducted in Africa have 
however found that ECG correlates very poorly with 
echocardiographic LV mass. Apart from detecting LVH, ECG 
also provides information related to arrhythmia, conduction 
defects and myocardial ischaemia. Factors affecting QRS voltage 
include race, body habitus, age, obesity and chest wall thickness.
Though the awareness and availability of echocardiography in 
teaching and private hospital is increasing, it is still not widely 
accessible because of high cost.  Echocardiography is the most 
widely used method for estimating ventricular mass by direct 
visualisation of the heart. Although M-mode echocardiography 
is most often used to evaluate LV mass, 2D and 3D echocardio-
graphy have also been used.  Nonetheless, serial estimates of 
LV mass are more reproducible by 2D than with M-mode Echo.
Regression of hypertrophy
Many studies(64,97) have shown that regression of left ventricular 
wall thickness and mass occur following administration of 
antihypertensive therapy and this should be one of the goals 





















be noted that regression of hypertension has also been demon-
strated using non pharmacological measures e.g. weight reduc-
tion and reduction in salt intake. Reduction of LV mass can be 
achieved in patients with hypertension and LVH without impair-
ing LV ejection fraction or cardiac output.(98)
Several meta-analyses(64,97) have demonstrated that the common 
classes of antihypertensive agents decrease LV mass with the 
exception of direct acting vasodilators (hydrallazine) and some 
beta blockers with intrinsic sympathomimetic activity.(99)
Benefi cial effects of reduction in LV mass include:
improved LV fi lling
increased coronary reserve
decreased cardiovascular mortality and morbidity
improved mid-wall fractional shortening
increased electrophysiological stability
CONCLUSION                                                                  
Hypertensive heart disease is prevalent in Africa and since 
hypertension is a treatable risk factor, there is need to create 
more awareness about the disease and educate our patients 
concerning drug compliance. Each patient should also be assessed 
for total cardiovascular risk. African countries should provide 
simple, cost effective hypertension guidelines for their people with 
the overall aim of preventing the devastating cardiac and other 
complications of hypertension within the populace. Hyper-
tensive heart disease in Africa continues to be an exciting area 
and more work needs to be done. There is also a need for 
longitudinal multicentre study in Africa, in order to assess the 
severity and burden of the disease. The INTERHEART study(100) 
has confi rmed the rarity of coronary artery disease in black 
Africans(101,102) and the major risk for coronary artery disease 
in Africa is  hypertension. Comparative studies between Africans 
and other populations were coronary artery disease is endemic 
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